• SEC Filings

On August 2, 2017, Novan, Inc. (the “Company”) held a webcast providing an updated corporate presentation that included certain preliminary information on the Company’s financial condition at June 30, 2017. Such information is based on the Company’s estimates as of the date of the presentation and is subject to the completion of the Company’s procedures for finalizing the Company’s financial results for the quarter ended June 30, 2017. Accordingly, the preliminary information may change, and those changes may be material. You should not place undue reliance on this preliminary estimate. The corporate presentation is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information contained in, or incorporated into, this Item 9.01, including the corporate presentation attached as Exhibit 99.1 to this Current Report, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

On August 2, 2017, the Company held a webcast providing an updated corporate presentation, as described above in Item 9.01. The corporate presentation is furnished herewith as Exhibit 99.1 to this Current Report.

See the Exhibit Index which follows the page of this Current Report on Form 8-K, which is incorporated herein by reference.

Novan, Inc. Exhibit
EX-99.1 2 novn-ex991_6.htm EX-99.1 novn-ex991_6.pptx.htm Novan Webcast August 2,…
To view the full exhibit click here

About Novan, Inc. (NASDAQ:NOVN)

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.